全口服抗病毒方案在996例HIV/HCV基因1型合并感染患者中的真实世界疗效
该观察性意向性治疗队列分析利用退伍军人事务临床病例登记系统,纳入996例启动12周LDV/SOF±RBV或OPrD±RBV的HIV/HCV GT1合并感染退伍军人。总体SVR为90.9%,肝硬化患者SVR显著低于无肝硬化者(85.9% vs 92.4%,P=.006),肝硬化是SVR降低的预测因素(OR 0.51,95%CI .31-.87;P=.01)。
要点
- HIV/HCV GT1合并感染患者全口服方案总体SVR达90.9%。
- 肝硬化与SVR降低独立相关(OR 0.51,95%CI .31-.87;P=.01)。
- 非裔美国人或PPI使用未显著降低LDV/SOF±RBV的SVR。
核心结论
- HIV/HCV GT1合并感染患者接受全口服抗病毒方案的SVR率较高。
- 肝硬化是SVR降低的预测因素,但非裔美国人种族或PPI使用与LDV/SOF±RBV的SVR降低无关。
- 含TDF的LDV/SOF方案未导致肾功能恶化。
研究设计与样本
- 观察性意向性治疗队列分析,使用退伍军人事务临床病例登记系统。
- 纳入996例启动12周LDV/SOF±RBV或OPrD±RBV的HIV/HCV GT1合并感染退伍军人。
主要发现
- 总体SVR为90.9%(823/905);LDV/SOF为92.1%(631/685),LDV/SOF+RBV为86.3%(113/131),OPrD为88.9%(24/27),OPrD+RBV为88.7%(55/62)。
- 肝硬化患者SVR为85.9%(176/205),无肝硬化者为92.4%(647/700)(P=.006)。
- 非裔美国人SVR为90.5%(546/603),其他人群为91.7%(277/302)。
- LDV/SOF±RBV联合PPI者SVR为89.7%(131/146),未联合PPI者为91.5%(613/670)。
- 肝硬化预测SVR降低(OR 0.51,95%CI .31-.87;P=.01)。
关键数值与推荐
- LDV/SOF与TDF无PI联用者肌酐变化中位数为0.18(IQR 0.08-0.30;n=372)。
- LDV/SOF与TDF/PI联用者肌酐变化中位数为0.17(IQR 0.04-0.30;n=100)。
- LDV/SOF不与TDF联用者肌酐变化中位数为0.15(IQR 0.00-0.30;n=423)。
临床怎么用
- 在HIV/HCV GT1合并感染的真实世界人群中,全口服方案可获得高SVR率。
- 肝硬化患者接受全口服方案时SVR率较低,需关注。
- LDV/SOF方案与TDF联用时未观察到肾功能恶化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND.: Large cohorts are needed to assess human immunodeficiency virus (HIV)/hepatitis C virus (HCV) real-world treatment outcomes. We examined the effectiveness of ledipasvir/sofosbuvir with or without ribavirin (LDV/SOF ± RBV) and ombitasvir/ paritaprevir/ritonavir plus dasabuvir (OPrD) ± RBV in HIV/HCV genotype 1 (GT1)-coinfected patients initiating HCV therapy in clinical practice. METHODS.: Observational intent-to-treat cohort analysis using the Veterans Affairs Clinical Case Registry to identify HIV/HCV GT1-coinfected veterans initiating 12 weeks of LDV/SOF ± RBV or OPrD ± RBV. Multivariate models of sustained virologic response (SVR) included age, race, cirrhosis, proton pump inhibitor (PPI) prescription, prior HCV treatment, body mass index, genotype subtype, and HCV treatment regimen. RESULTS.: Nine hundred ninety-six HIV/HCV GT1-coinfected veterans initiated therapy: 757 LDV/SOF, 138 LDV/SOF + RBV, 28 OPrD, and 73 OPrD + RBV. Overall SVR was 90.9% (823/905); LDV/SOF 92.1% (631/685), LDV/SOF + RBV 86.3% (113/131), OPrD 88.9% (24/27), and OPrD + RBV 88.7% (55/62). SVR was 85.9% (176/205) and 92.4% (647/700) in those with and without cirrhosis (P = .006). SVR was similar between African Americans (90.5% [546/603]) and all others (91.7% [277/302]). PPI use with LDV/SOF ± RBV did not affect SVR (89.7% [131/146] with PPI and 91.5% [613/670] without PPI). Cirrhosis was predictive of reduced SVR (0.51 [95% confidence interval {CI}, .31-.87]; P = .01). Median creatinine change did not differ among patients receiving LDV/SOF and tenofovir disoproxil fumarate (TDF) without a protease inhibitor (PI) (0.18 [interquartile range {IQR}, 0.08-0.30]; n = 372), LDV/SOF and TDF/PI (0.17 [IQR, 0.04-0.30]; n = 100), and LDV/SOF without TDF (0.15 [IQR, 0.00-0.30]; n = 423). CONCLUSIONS.: SVR rates in HIV/HCV GT1-coinfected patients were high. African American race or PPI use with LDV/SOF ± RBV was not associated with lower SVR rates, but cirrhosis was. Renal function did not worsen on LDV/SOF regimens with TDF.
引用
- Bhattacharya D, Belperio PS, Shahoumian TA, et al. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice. Clin Infect Dis. 2017. PMID: 28199525. doi:10.1093/cid/cix111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。